We are live on ! Find out more

Bristol-Myers Squibb

BMY

Market cap $129B

63.34 USD

+1.63

2.64%

At close Updated Nov 4, 9:45 AM EST

1 day

2.64%

5 days

3.84%

1 month

7.7%

3 months

-3.87%

6 months

10.39%

Year to date

18.48%

1 year

38.93%

5 years

6.9%

10 years

24.17%

About: Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Employees: 32,500

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 52.8%

Neutral 38.7%

Negative 8.6%

The Motley Fool

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

AbbVie is successfully navigating a critical transition period as newer immunology drugs offset revenue declines from legacy products. Bristol Myers Squibb offers a high-margin portfolio focused on oncology and hematology with a significantly lower valuation multiple.

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

Zacks Investment Research

BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Bristol Myers Squibb gains 3% after beating third-quarter estimates, as its Growth Portfolio and promising pipeline support revenue prospects despite generic competition.

BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)

Bristol-Myers Squibb is downgraded to 'Hold' as its current valuation appears optimistic ahead of looming patent cliffs. BMY's Growth Portfolio now comprises ~59% of revenues, with 8 medicines annualizing above $1 billion, partially offsetting legacy portfolio declines. DCF analysis values BMY at $61.19 per share, nearly matching the current price, highlighting limited upside even with near flat forward revenue growth.

Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)

Zacks Investment Research

BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

BMY raises its 2026 revenue outlook on strong Growth Portfolio sales, even as earnings pressure, patent expirations and drug launch challenges remain in focus.

BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

Zacks Investment Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

How Bristol Myers's CEO Challenged the Company's Managers

When Alan and I talked with Chris Boerner recently, a critical aspect of his leadership style was apparent immediately: He confronts issues head on.

How Bristol Myers's CEO Challenged the Company's Managers

Bristol Myers Squibb Q3 Earnings Call Highlights

Bristol Myers Squibb NYSE: BMY raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a series of clinical readouts and manufacturing investments intended to support its next generation of launches.

Bristol Myers Squibb Q3 Earnings Call Highlights

The Motley Fool

Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Bristol Myers Squibb's Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain to $13.1 billion. Adjusted EPS fell 17% to $1.35, but mostly because of deal accounting, not a weaker core business.

Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Zacks Investment Research

BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook

Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.

BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook

Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript

Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript

Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™